GeneHealth - Your precision medicine

Thromboangiitis Obliterans

Disease Details

Family Health Simplified

Buy Membership

Description: Thromboangiitis obliterans, also known as Buerger’s disease, is a rare inflammatory condition affecting small and medium-sized arteries and veins, leading to blood vessel blockage, reduced blood flow, and tissue damage typically in the extremities.
Type: Thromboangiitis obliterans (also known as Buerger's disease) is a type of vasculitis that affects small- and medium-sized arteries and veins. It is not typically associated with genetic transmission but is strongly linked to tobacco use.
Signs And Symptoms: There is a recurrent acute and chronic inflammation and thrombosis of arteries and veins of the hands and feet. The main symptom is pain in the affected areas, at rest and while walking (claudication). The impaired circulation increases sensitivity to cold. Peripheral pulses are diminished or absent. There are color changes in the extremities. The colour may range from cyanotic blue to reddish blue. Skin becomes thin and shiny. Hair growth is reduced. Ulcerations and gangrene in the extremities are common complications, often resulting in the need for amputation of the involved extremity.
Prognosis: Buerger's is not immediately fatal. Amputation is common and major amputations (of limbs rather than fingers/toes) are almost twice as common in patients who continue to smoke. Prognosis markedly improves if a person quits smoking. Female patients tend to show much higher longevity rates than men. The only known way to slow the progression of the disease is to abstain from all tobacco products.
Onset: Thromboangiitis obliterans, also known as Buerger's disease, typically has an onset in young adults between ages 20 to 40, more commonly affecting males and those with a history of heavy tobacco use. The cause of the disease remains unknown.
Prevalence: Thromboangiitis obliterans, also known as Buerger’s disease, is relatively rare. It primarily affects young male smokers, typically between the ages of 20 and 40. The exact prevalence is not well-documented, but it is more common in regions with higher rates of tobacco use, including parts of Asia and the Middle East. Overall, it is considered an uncommon condition in the general population.
Epidemiology: Buerger's is more common among men than women. Although present worldwide, it is more prevalent in the Middle East and Far East. Incidence of thromboangiitis obliterans is 8 to 12 per 100,000 adults in the United States (0.75% of all patients with peripheral vascular disease).
Intractability: Thromboangiitis obliterans, also known as Buerger's disease, can be intractable because it is a chronic and progressive condition with no cure. The primary treatment involves smoking cessation, which is crucial for halting disease progression. However, if the patient continues to smoke, the disease often persists and may lead to severe complications, including tissue loss and amputation.
Disease Severity: Thromboangiitis obliterans, also known as Buerger's disease, varies in severity. It can range from mild discomfort to severe pain and debilitating complications. Severe cases may lead to tissue damage, ulcers, and even gangrene, necessitating amputation if not managed properly. Symptoms usually worsen over time, particularly if smoking, a major risk factor, continues. Early diagnosis and smoking cessation are crucial to prevent disease progression and severe outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:12918
Pathophysiology: There are characteristic pathologic findings of acute inflammation and thrombosis (clotting) of arteries and veins of the hands and feet (the lower limbs being more common). The mechanisms underlying Buerger's disease are still largely unknown, but smoking and tobacco consumption are major factors associated with it. It has been suggested that the tobacco may trigger an immune response in susceptible persons or it may unmask a clotting defect, either of which could incite an inflammatory reaction of the vessel wall. This eventually leads to vasculitis and ischemic changes in distal parts of limbs.A possible role for Rickettsia in this disease has been proposed.
Carrier Status: Thromboangiitis obliterans, also known as Buerger's disease, does not have a carrier status as it is not a genetic or hereditary condition. It is a rare disease that typically affects the small and medium-sized arteries and veins, primarily in the arms and legs, and is strongly associated with tobacco use.
Mechanism: Thromboangiitis obliterans, also known as Buerger's disease, primarily affects small- and medium-sized arteries and veins, leading to inflammation and thrombosis (clotting), which can result in reduced blood flow and tissue damage.

Mechanism:
The disease is characterized by segmental, inflammatory, and thrombotic processes in the vascular system, which leads to occlusion of the affected vessels. This vascular inflammation and clotting impairs blood flow, often resulting in ischemia and pain in the extremities, and can lead to ulceration or gangrene.

Molecular Mechanisms:
1. **Endothelial Dysfunction**: Initial endothelial damage or dysfunction is believed to play a significant role, contributing to the subsequent inflammatory process.
2. **Inflammatory Cytokines**: Elevated levels of inflammatory mediators such as tumor necrosis factor (TNF) and interleukins (e.g., IL-6) are often observed, promoting vascular inflammation and thrombosis.
3. **Immune Response**: There appears to be an autoimmune component, with evidence of heightened immune activity against endothelial cells and elevated levels of circulating immune complexes.
4. **Thrombogenesis**: Enhanced thrombogenesis involves platelet activation and aggregation, which contribute to clot formation within the vessels.
5. **Genetic Predisposition**: Certain genetic factors may predispose individuals to the disease, possibly influencing immune and inflammatory responses.

Overall, the pathophysiology of thromboangiitis obliterans involves a complex interplay of vascular inflammation, immune responses, and thrombotic activities leading to occlusive vascular disease.
Treatment: Smoking cessation has been shown to slow the progression of the disease and decrease the severity of amputation in most patients, but does not halt the progression.
In acute cases, drugs and procedures which cause vasodilation are effective in reducing pain experienced by patient. For example, prostaglandins like Limaprost are vasodilators and give relief of pain, but do not help in changing the course of disease. Epidural anesthesia and hyperbaric oxygen therapy also have vasodilator effect. There is moderate certainty evidence that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for relieving rest pain and healing ischemic ulcers. No difference have been detected between iloprost or clinprost (prostacyclin) and alprostadil (prostaglandin analogue) for relieving pain and healing ulcers.In chronic cases, lumbar sympathectomy may be occasionally helpful. It reduces vasoconstriction and increases blood flow to limb. It aids in healing and giving relief from pain of ischemic ulcers. Bypass can sometimes be helpful in treating limbs with poor perfusion secondary to this disease. Use of vascular growth factor and stem cell injections have been showing promise in clinical studies. There may be a benefit of using bone marrow-derived stem cells in healing ulcers and improving pain-free walking distance, but larger, high-quality trials are needed. Debridement is done in necrotic ulcers. In gangrenous digits, amputation is frequently required. Below-knee and above-knee amputation is rarely required.Streptokinase has been proposed as adjuvant therapy in some cases.Despite the clear presence of inflammation in this disorder, anti-inflammatory agents such as corticosteroids have not been shown to be beneficial in healing, but do have significant anti-inflammatory and pain relief qualities in low dosage intermittent form. Similarly, strategies of anticoagulation have not proven effective.
physical therapy: interferential current therapy to decrease inflammation.
Compassionate Use Treatment: Thromboangiitis obliterans, also known as Buerger's disease, primarily affects blood vessels in the arms and legs. It is characterized by inflammation and thrombosis (clotting) in small and medium arteries and veins, leading to restricted blood flow and potential tissue damage.

1. **Compassionate Use Treatment**:
- **Iloprost**: A prostaglandin analog that helps in vasodilation and is sometimes used on a compassionate basis to treat severe cases of Buerger's disease.

2. **Off-Label or Experimental Treatments**:
- **Rheopheresis**: An extracorporeal procedure aimed at removing fibrinogen and other large proteins that may contribute to blood viscosity.
- **Stem Cell Therapy**: Involves the use of autologous bone marrow-derived stem cells to promote angiogenesis (formation of new blood vessels).
- **Bosentan**: An endothelin receptor antagonist primarily used for pulmonary arterial hypertension, potentially effective for severe digital ischemia in Buerger's disease.

These treatments are generally considered when conventional therapies fail and are aimed at improving blood flow and reducing symptoms.
Lifestyle Recommendations: Thromboangiitis obliterans, also known as Buerger's disease, is a rare vasculitis that primarily affects the small and medium-sized arteries and veins of the extremities. Here are some lifestyle recommendations for managing this condition:

1. **Smoking Cessation**: The most critical step in managing thromboangiitis obliterans is to quit all forms of tobacco use. This includes cigarettes, cigars, chewing tobacco, and exposure to secondhand smoke. Continuing to smoke can severely worsen the condition and may lead to amputation.

2. **Avoid Cold Exposure**: Keeping the extremities warm is crucial as cold can exacerbate symptoms. Wearing warm gloves and socks, and avoiding prolonged exposure to cold temperatures are recommended.

3. **Exercise Regularly**: Gentle, regular exercise, such as walking, can help improve circulation. However, it's important to avoid over-exertion and to consult a healthcare provider for a tailored exercise regimen.

4. **Good Foot Care**: Since the disease affects the extremities, proper foot care is essential. This includes regularly checking for sores or ulcers, keeping feet clean and dry, and wearing well-fitted shoes to prevent injury.

5. **Stress Management**: Techniques such as meditation, deep breathing, and yoga can help reduce stress, which may improve overall health and potentially help in managing symptoms.

6. **Balanced Diet**: Eating a healthy diet can improve overall vascular health. Focus on a diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats.

7. **Avoiding Certain Medications**: Some medications can worsen vascular symptoms. Always inform your healthcare provider of all medications you are taking.

8. **Routine Medical Follow-Up**: Regular visits to your healthcare provider are important to monitor the condition and manage symptoms effectively.

Adhering to these lifestyle recommendations can help manage the symptoms and progression of thromboangiitis obliterans.
Medication: Thromboangiitis obliterans, also known as Buerger's disease, primarily requires smoking cessation as the most crucial intervention, as the disease is strongly associated with tobacco use. Medications may include vasodilators like nifedipine, anti-inflammatory drugs, and anticoagulants such as aspirin. However, effectiveness varies, and managing symptoms primarily focuses on lifestyle changes and avoiding tobacco.
Repurposable Drugs: Currently, there are no widely recognized repurposable drugs for thromboangiitis obliterans (Buerger's disease). The primary treatment remains smoking cessation, as tobacco use is a major contributing factor. Management typically focuses on improving blood flow and managing symptoms. New therapies and studies are ongoing, so consult medical literature and professionals for the latest developments.
Metabolites: Thromboangiitis obliterans (Buerger's disease) is primarily a small and medium-sized artery and vein occlusive disease, with its pathogenesis not well-understood in terms of specific metabolites. The condition is strongly associated with tobacco use, and cessation of smoking is crucial for management. No specific metabolites are distinctly linked to this disease for diagnostic or therapeutic purposes.
Nutraceuticals: There is limited scientific evidence supporting the use of nutraceuticals in the treatment of thromboangiitis obliterans (Buerger's disease). This condition is primarily managed through smoking cessation, medication to improve blood flow, and sometimes surgical interventions. Always consult a healthcare professional before using any nutraceuticals or alternative therapies for this condition.
Peptides: Thromboangiitis obliterans, also known as Buerger's disease, is a rare condition that involves inflammation and thrombosis (clotting) in small and medium-sized blood vessels, primarily in the extremities. It is strongly associated with tobacco use.

Research into peptides for thromboangiitis obliterans is limited, and there are no well-established peptide therapies specifically for this condition. Treatment focuses on smoking cessation and improving blood flow to the affected areas. Nanotechnology applications, including nanoparticles, are still in the experimental stages for this disease and are not part of standard clinical practice. These might be explored for targeted drug delivery or imaging in the future.